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Background Regional German studies estimated the prevalence of undiagnosed diabetes to 
be almost as high as the prevalence of diagnosed diabetes. Even before symptoms of diabetes 
occur, diabetes related secondary diseases can be developing and cause increased health care 
expenditures. The German Diabetes Association recommends the application of the German 
Diabetes Risk Score (German DRS) to screen for undiagnosed diabetes and thus enable early 
treatment of diabetic individuals. 
Methods Data from the representative German National Health Interview and 
Examination Survey 1998 (N=7124), including a sample of the residential population aged 
18-79 years, was used to compute the German DRS. Participants with prevalent diabetes or 
missing data were excluded from analyses (N=718). Correlation between score and 
biomarkers related to type 2 diabetes was assessed by Pearson’s correlation coefficients. 
Sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC) 
were calculated for both undiagnosed diabetes (glycosylated haemoglobin (HbA1c) ≥6.5%; 
fasting plasma glucose (FPG) ≥126 mg/dl) and intermediate hyperglycaemia (HbA1c: 5.7-
6.4%; FPG: 100-125 mg/dl). 
Results Among the 6406 subjects, on average women had a lower score value than 
men. The German DRS was significantly negatively correlated with HDL-cholesterol among 
both genders while it was significantly positively correlated with glucose, HbA1c, 
triglycerides, total cholesterol, γ-glutamyltransferase, and alanintransferase. Sensitivity and 
specificity for undiagnosed diabetes at a cut point of ≥500 was 93.9/50.4 using FPG and 
91.2/56.6 using HbA1c as diagnostic criterion. For intermediate hyperglycaemia it was 
70.9/63.0 applying FPG and 67.3/67.2 applying HbA1c for diagnosis. The estimated AUC for 
undiagnosed diabetes was 0.79 using FPG and 0.84 using HbA1c. AUC values for 
intermediate hyperglycaemia were 0.72 applying FPG and 0.74 using HbA1c. 
Conclusion Compared to two other German study populations, the German DRS yielded 
similar discriminatory ability for undiagnosed diabetes among an 18-79 years old German 
survey population. Further research with regard to identification of high risk groups for 
diabetes and to differences in performance of the German DRS between both genders and 
different age-groups would be useful to improve efficiency of the German DRS as a screening 





Diabetes mellitus is a chronic metabolic disease caused by either insufficient pancreatic 
insulin secretion, deficient insulin action in the body, or a combination of both. Diabetes leads 
to hyperglycaemia and can cause several long-term complications, e.g. retinopathy possibly 
leading to blindness, nephropathy possibly leading to renal failure, or peripheral neuropathy 
increasing the risk of amputations (1, 2). About 346 million people all over the world already 
suffer from diabetes (3). However, following a worldwide trend the prevalence of diabetes 
among the Germany population is expected to further increase within the next years, causing 
rising health care expenditures and decreasing quality of life (4-6). 
The health care burden of diabetes could possibly be decreased by lifestyle interventions 
aiming to prevent development of diabetes and by early treatment of those who already suffer 
from diabetes (7-11). Thus, it is important to identify people at increased risk for developing 
future diabetes and to detect those suffering from undiagnosed diabetes at an early stage (11). 
For these reasons, several diabetes risk scores based on a variety of risk factors have been 
developed in different countries (10, 12-17). However, the German Diabetes Association 
recommends the application of the German Diabetes Risk Score (German DRS) to screen for 
undiagnosed diabetes among the German population (1). 
1.2 Objectives 
The intentions of the present study were 
- To compute the German DRS for participants of the German National Health Interview 
and Examination Survey 1998 (GNHIES). 
- To analyse the distribution of the German DRS among the survey population. 
- To examine correlations between biomarkers related to pathophysiology of type 2 diabetes 
and the computed German DRS. 
- To examine the performance of the German DRS when used as a screening tool for 
undiagnosed diabetes and intermediate hyperglycaemia among the survey population.
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1.3 Overview of diabetes mellitus 
Diabetes mellitus is one of the leading causes of premature death worldwide along with other 
non-communicable diseases, e.g. cardiovascular diseases (CVD) and cancer (18). Three major 
forms of diabetes mellitus have been defined. First, type 1 diabetes mellitus, which is caused 
by autoimmune destruction of the pancreatic ß-cells resulting in a lack of insulin production. 
Type 1 diabetes accounts for about 5-10% of all diabetic cases and is not preventable 
according to present understanding (1-3). Second, type 2 diabetes mellitus, which is thought 
to be caused by an interaction of several factors, e.g. genetic predisposition, overweight, 
sedentary lifestyle. Therefore, to a large part it is regarded as being preventable (3, 11, 19). 
Patients suffering from type 2 diabetes usually show insulin resistance and relative insulin 
deficiency to some degree (1, 2, 6). Type 2 diabetes mellitus accounts for approximately 80-
90% of all diabetic cases in adults (6). Finally, the third type, gestational diabetes is 
characterized by hyperglycaemia, which occurs first during pregnancy but does usually not 
persist after delivery (1, 2). Other types of diabetes are associated, for example, with genetic 
defects of the pancreatic ß-cells, diseases of the exocrine pancreas, or infections. However, 
their prevalence among the German population is rather low (1, 2). 
In Germany, about 9% of all adults suffered from diagnosed diabetes mellitus accounting for 
approximately six million prevalent cases in 2009. The prevalence of diabetes rises with 
increasing age and decreasing socio-economic status (5, 6, 20). Compared to 2002/03, the 
prevalence of diagnosed diabetes has increased in Germany and is expected to further grow 
due to demographic changes and changes of lifestyle (5, 21-23). However, also improved 
diagnostic measures might add to an increase in prevalence of diagnosed diabetes (24). 
Diabetes mellitus has severe effects on the body and elevates the risk of suffering from, e.g. 
CVD, kidney failure, blindness, neuropathy, and limb amputation (3, 11, 19). Therefore, it 
decreases life expectancy, increases costs for medical care, and diminishes ability to work (6, 
25). In Germany, diabetes and its complications and subsequent diseases led to increased 
direct health care costs of approximately € 19 billion in 2007, when compared to non-diabetic 
patients (1.8 times higher costs) (5, 24). Costs indirectly connected with diabetes through 




Studies have shown that a considerably large part of the worldwide population also suffers 
from undiagnosed diabetes (27). However, currently representative data about the prevalence 
of undiagnosed diabetes among the German population are not available (6). Though, 
regionally confined data indicate that the prevalence of undiagnosed diabetes is about as high 
as the prevalence of diagnosed diabetes among a study population from Southern Germany 
(28, 29). Due to lacking clinical symptoms of the disease at early stages, the diagnosis of 
type 2 diabetes usually occurs several years after its onset (11). However, even before 
symptoms of diabetes are shown, the risk of developing diabetes related secondary diseases is 
already increased. Treatment of these secondary diseases is approximately three times more 
expensive than the health care costs caused by treating diabetes itself (26). Consequently, 
early detection of individuals suffering from undiagnosed diabetes and those being at 
increased risk of developing type 2 diabetes might help to decrease total health care 
expenditures and improve overall wellbeing (3, 11, 24, 26). 
1.4 Overview of different diabetes risk scores developed or applied in Germany 
Several diabetes risk scores or risk models have been developed in different countries 
intended to identify individuals at high risk of developing diabetes and those suffering from 
undiagnosed diabetes, respectively (10, 12-17). The following paragraph presents and 
compares diabetes risk scores/models which have either been developed or applied in 
Germany or both. As shown in table 1, in Germany four different diabetes risk scores/models 
have been developed (German DRS, IRIS II (International randomized trial of Interferon/Ara-
C versus ST1571) score, KORA (Cooperative Health Research in the Region of Augsburg) 
type 2 diabetes prediction models, PROCAM (Prospective Cardiovascular Münster) multiple 
logistic function model) (10, 30-32). Besides, six diabetes risk scores either originated in 
foreign countries (Cambridge DRS, FINDRISK (Finish Diabetes Risk Score), Framingham 
Simple Clinical Model, Predictive Clinical Model (San Antonio Heart Study), Rotterdam 
Diabetes Questionnaire) or in Germany (German DRS) have been applied in further German 
study populations (33) (10, 34-40). Moreover, two scores developed in Germany (KORA type 
2 diabetes prediction model, PROCAM multiple logistic function model) have been externally 
validated in the Netherlands and in China, respectively (41, 42). Finally, two risk scores, one 
developed in Finland (FINDRISK) and one in Germany (German DRS), have been modified 
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1 = originally also history of diabetes in siblings was used, but this information was not available for the KORA sample (33) 
2 = history of high blood glucose levels was used in original score, but not in validation study (12, 33) 
3 = family history of T2DM  was not included in original FINDRISK score, but the authors suggest to further include this risk factor in the 
score (suggestion: 5 score points for first degree family history and 3 score points for second degree family history) (12) 
4 = due to family history of T2DM, obesity, or dyslipoproteinemia (35) 
5 = questions about dietary habits and PA did not add much predictive power (35) 
6 = model 2 and model 3 differ from the original KORA models (33, 41) 
AUC= area under the receiver operating characteristic curve (ROC curve) (discriminatory ability); Sensitivity (true-positive probability) = is 
the probability of identifying any person suffering from the disease (diabetes) with the help of the used score (45); Specificity (true-negative 
probability) = is the probability of identifying any person not suffering from the disease (diabetes) with the help of the used score (45); PG = 
post-load glucose level; IFG (impaired fasting glucose) = 100 – 125 mg/dl (2); IGT (impaired glucose tolerance) =2-h value in  oral glucose 
tolerance test 140 – 199 mg/dl (2); MS = metabolic syndrome; WC = waist circumference; PA = physical activity; BP = blood pressure; 
BMI = Body Mass Index (kg/m²); T2DM = type 2 diabetes mellitus; CS = cross-sectional; CSS = cross-sectional study; HOMA-IR = 
homeostasis model assessment of insulin resistance; IR = insulin resistance; 
KORA = Cooperative Health Research in the Region of Augsburg;  
FINDRISK = Finish Diabetes Risk Score; 
EPIC = European Prospective Investigation into Cancer and Nutrition;  
MeSyBePo = Metabolic Syndrome Berlin Potsdam Study;  
TÜF = Tübingen Family Study for Type 2 Diabetes;  
PROCAM = Prospective Cardiovascular Münster;  
IRIS = International Randomized trial of Interferon/Ara-C versus ST1571;  
PREVEND = Prevention of renal and vascular end stage disease 
Compared to original studies, in confirmative studies, most risk scores show a lower ability to 
discriminate between prevalent undiagnosed diabetic cases and non-diabetic individuals and 
between individuals at high risk for diabetes and low risk for diabetes. Exceptions are, the 
predictive clinical model (San Antonio Heart Study), the Framingham simple clinical model, 
and the KORA S4/F4 type 2 diabetes prediction model. One of the reasons for this result is 
the fact that original study populations and populations of validation studies usually differ in 
their characteristics. A decreased accuracy (discriminatory ability) is reflected by a smaller 
area under the receiver operating characteristic (AUC) curve than in an original study. A ROC 
curve is created by plotting the sensitivity (true-positive probability) against the false-positive 
probability (1-specificity) of each possible cut-off point of a chosen prediction model. The 
AUC values range from 0.5 to 1.0, 0.5 indicates a non-informative test result and 1.0 a perfect 
prediction (accuracy) of the model (44, 46). Especially, when the risk score has been 
developed in a foreign country its detected accuracy in the validation study shrinks (10, 12, 
13, 15, 16, 33, 38, 41, 42). This is one of the reasons, why it is recommended to validate the 
performance of the risk score within the target population before implementing it as a 
screening tool, for example (33, 47). Based on the same reason Herman at al. recommend, to 
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rather implement a risk score as screening tool that has been developed in the same 
population (48). 
Altogether, five diabetes risk scores/risk prediction models used only non-invasive measures 
(Cambridge DRS, FINDRISK, German DRS, KORA S4/F4 type 2 diabetes prediction model 
1, Rotterdam diabetes study questionnaire) (10, 12-14, 31). Inclusion of biochemical markers 
led to an improvement in the accuracy and in the prediction of an increased risk for 
type 2 diabetes in the KORA type 2 diabetes prediction model and the German DRS (31, 44). 
However, inclusion of genetic markers did not further improve prediction of type 2 diabetes 
risk in the German DRS (44). The application of the predictive clinical model of the San 
Antonio Heart Study and the extended version of the German DRS yielded the highest AUCs 
(0.90). Both used non-invasive and invasive measures e.g. HDL-cholesterol and fasting 
glucose level (15, 44). Among the risk scores solely based on non-invasive measures, the 
simplified alternative version of the FINDRISK score (categorical model: AUC=0.86; 
continuous model: AUC=0.88) and the classic version of the German DRS (AUC=0.83) 
showed the highest discriminatory ability for undiagnosed diabetes (10, 36). 
As mentioned before, the aim of diabetes risk scores is either to screen for undiagnosed 
diabetes or to predict the individual risk of developing diabetes. The German DRS has been 
developed based on a prospective cohort study and is therefore able to identify individuals at 
high risk for diabetes. In two validation studies it has been demonstrated that it also shows 
high discriminatory ability with regard to screening for undiagnosed diabetes (10, 39). On the 
other hand, since it is based on cross-sectional data, the simplified FINDRISK version is only 
intended to be used to screen for undiagnosed cases of diabetes (36). As a screening tool it is 
an advantage to use non-invasive measures only as it is less costly (49). Besides, it is less time 
consuming and more convenient for the participants compared to, e.g. an oral glucose 
tolerance test (OGTT) or other invasive measures. A screening tool based on non-invasive 
measures might thus lead to a higher compliance among participants (15, 50). 
Both, German DRS and simplified FINDRISK version have been developed based on 
German study populations and show a high discriminatory ability (AUC value) (10, 36, 39). 
Nevertheless, the German DRS seems to have the best applicability as a screening instrument 
among the German population. First of all, the German DRS is based on a large cohort 
population and has been validated in three other German study populations, showing high 
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accuracy for prediction of increased risk for future diabetes and for detection of undiagnosed 
diabetes (10). In contrast, the development of the FINDRISK score was based on a Finish 
study population and the simplified FINDRISK version was based on a relatively small 
sample without being validated yet (12, 36). Moreover, the study population used to develop 
the simplified FINDRISK version was at increased risk for developing the metabolic 
syndrome and is therefore not generalizable to the common German population (36). Indeed, 
also a modified German version of FINDRISK has been developed (51). However, it has only 
been validated in one cross-sectional and one cohort study with both rather small sample 
sizes. Nevertheless, it yielded only slightly lower accuracy for prediction of increased risk for 
diabetes and similar accuracy for detection of undiagnosed diabetes compared to the German 
DRS (35, 36). Though, the high detected accuracy can possibly be explained by the fact that 
the variable “history of high blood glucose” is used in all FINDRISK versions. It includes the 
prediabetic states of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) but 
also diabetes itself, which obviously is strongly related to the identification of “undiagnosed 
diabetes” (39). Other risk scores developed in Germany, like the PROCAM multiple logistic 
function model and the KORA S4/F4 type 2 diabetes prediction model, have not been 
validated in German study populations yet and were based on smaller sample sizes. Besides, 
all other scores using only non-invasive measures yielded lower AUC values and/or were 
validated in a lower number of studies (see table 1). In summary, the German DRS shows a 
high accuracy for undiagnosed diabetes, it is based on a large German cohort study, it has 
been validated in three other studies, and it only uses non-invasive measures. Therefore, the 
German DRS is used as a screening instrument in a representative sample of the German 
population in the present investigation. 
2. Methods 
2.1 German National Health Interview and Examination Survey 1998 
For the purpose of the following analyses, data from the cross-sectional GNHIES conducted 
from October 1997 until March 1999 was used. The survey consists of a representative 
sample of the residential German population and comprises 7124 subjects aged between 
18 and 79 years including 3450 men and 3674 women. A two-stage stratified and clustered 
sampling technique was used. First, a representative sample of 130 communities or 
community districts (sampling points) distributed all over Germany was randomly chosen, 
stratified for federal state and community size. Among these sample points 80 were located in 
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western Germany and 40 in eastern Germany. Second, in each of the chosen sampling points 
the local population registry was used to randomly select residents with regard to gender and 
age. The overall response rate of the GNHIES was 61.4%. To ensure statistically sound 
results regarding analysis of differences between eastern and western Germany a 
disproportionally higher number of participants was chosen from eastern Germany. For all 
analyses of the data a weighting factor was used to adjust for variations between 
characteristics of the selected participants and demographic characteristics of the residential 
German population. This step improves representativeness of the sample. The described 
procedure guarantees a representative sample of the German population (52, 53). 
The GNHIES consists of a core survey and five more specific modules (environmental 
survey, nutrition survey, folate study, mental health survey, and pharmaceutical survey) (54). 
For the present analyses, information from the core survey and the nutrition survey were used. 
The core survey included all 7124 participants and encompassed a self-administered 
questionnaire about health status, socio-economic status, living conditions, nutritional 
behaviour (FFQ), smoking, and physical activity, a medical and anthropometric examination, 
a computer assisted personal interview (CAPI) by a medical doctor about the participant’s 
medical history and drug intake, and laboratory diagnostics of blood and urine samples (54). 
In the nutrition survey the usual dietary intake of the past four weeks was assessed for a 
subsample of 4030 participants. For that purpose, a personal interview was performed by 
qualified nutritionists using DISHES (Dietary Interview Software for Health Examination 
Studies), which is a dietary assessment software based on the dietary history method. 
DISHES was validated against a 3 day weighted dietary record and a 24 hour dietary recall. 
Pearson’s correlation coefficients for macronutrients ranged between 0.34 and 0.69 for the 
3 day weighted record. The correlation between DISHES and the 24 hour dietary recall for 
macronutrients ranged between 0.27 and 0.65 (55). 
2.2 Subjects 
After exclusion of subjects already suffering from diagnosed diabetes reported in the medical 
interview (N = 369), subjects who reported to use blood sugar medication (N = 10), and 
subjects with missing information about any of the variables used to calculate the German 
DRS (N = 339), a total of 6406 subjects remained for further analyses. 
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2.3 German Diabetes Risk Score 
The German DRS was developed using a subsample of the EPIC (European Prospective 
Investigation into Cancer and Nutrition) Potsdam cohort study (N = 25,167, age = 35-65 
years). It was validated against data from three other German studies (EPIC-Heidelberg, 
Tübingen Family Study for Type 2 Diabetes (TÜF), Metabolic Syndrome Berlin Potsdam 
(MeSyBePo) study). The German DRS is intended to be used to calculate the individual five 
year probability of developing type 2 diabetes mellitus. For example, a score < 423 points is 
equivalent to a possibility of less than 1% for developing diabetes in the following 5 years, 
whereas ≥ 658 points are equivalent to a probability of more than 10%. The risk score is 
supposed to be used to identify persons at high risk of developing diabetes. It can further be 
used to identify individuals with undiagnosed diabetes (10, 39). For the calculation of the 
original German DRS, only variables measured non-invasively and being significantly 
associated with diabetes risk were included (10). The German DRS is computed by the 
following equation (10, 44): 
German DRS = 7.4 x waist (cm) – 2.4 x height (cm) + 4.3 x age (years) + 46 x history 
of hypertension (self-reported) + 49 x red meat (each 150 g/day) – 9 x whole-grain 
bread (each 50 g/day) – 4 x coffee (each 150 g/day) – 20 x moderate alcohol (between 
10 and 40 g/day) – 2 x physical activity (h/week) + 24 x former smoker + 64 x current 
heavy smoker (≥ 20 cigarettes/day) 
All multipliers are based on the calculated ß-coefficients in the original Cox regression model. 
The probability of developing diabetes in the following five years is calculated by (10): 
p (diabetes) = 0.999854exp(score points/100) 
14 
 
2.4 Definition and assessment of variables 
For calculation of the German DRS for GNHIES participants all variables shown in table 2 
were used. 
Table 2. Comparison between variables used from EPIC-Potsdam and those used from the GNHIES to 
compute the German DRS. 
Variable German DRS/EPIC-Potsdam German DRS/GNHIES 
Waist 
circumference 
Anthropometric measurements (cm) 
- performed by interviewers trained in 
anthropometric measurement 
- measured accurately to the next 0.5 cm 
Anthropometric measurements (cm) 
- performed by trained health professionals 
- measured accurately to the next 0.5 cm 
Height Anthropometric measurements (cm) 
- performed by interviewers trained in 
anthropometric measurement 
- measured accurately to the next 0.1 cm 
Anthropometric measurements (cm) 
- performed by trained health professionals 
- measured accurately to the next 0.1 cm 
Age Standardised self-administered 
questionnaire 
- years 




Standardised personal interview 
- performed by a trained physician 
- self-reported (yes/no) 
CAPI 
- performed by a trained physician 




- asking for frequencies and amounts of 
intake of different kinds of red meat 
- categories from “never” to “five 
times/day or more” 
- estimation of portion size by using 
photographs of standard portion sizes 
- g/day 
FFQ (core survey) 
- asking for frequencies of overall meat 
intake (including poultry) 
- categories from “(almost) never” to 
“several times per day” 
DISHES (subsample, specific module) 
- Estimated average intake (g/d) for each 
frequency category (FFQ) based on data of 





- Asking for frequencies and amounts of 
intake of whole grain bread and rolls 
- categories from “never” to “five 
times/day or more” 
- estimation of portion size by using 
photographs of standard portion sizes 
- g/day 
FFQ (core survey) 
- asking for frequencies of consumption of 
whole grain bread and rolls 
- categories from “(almost) never” to 
“several times per day” 
DISHES (subsample, specific module) 
- Estimated average intake (g/d) for each 
frequency category (FFQ) based on data of 
the German Nutrition Survey (dietary 
history method) 
Coffee intake Semiquantitative FFQ 
- Asking for frequencies and amount of 
intake of coffee with caffeine 
- categories from “never” to “five 
times/day or more” 
- estimation of portion size by using 
photographs of standard portion sizes 
- g/day 
FFQ (core survey) 
- Asking for frequencies of coffee 
consumption with caffeine 
- categories from “(almost) never” to 
“several times per day” 
DISHES (subsample, specific module) 
- Estimated average intake (g/d) for each 
frequency category (FFQ) based on data of 







- Asking for frequencies, type of 
beverage and amount 
- categories from “never” to “five 
times/day or more” 
- type of beverages (beer, wine, fruit 
wine, sparkling wine, distilled spirits) 
- estimation of portion size by using 
photographs of standard portion sizes 
(glasses or bottles) 
- calculation of alcohol intake (ethanol 
in g/d) based on the German Food 
Code and Nutrient Data Base version 
II.3 (56) 
Semiquantitative FFQ (core survey) 
- asking for frequencies, type of beverage 
and amount 
- categories from “(almost) never” to 
“several times per day” 
- type of beverage (beer, wine, fruit wine, 
sparkling wine, distilled spirits) 
- estimation of portion size by asking for 
litre amounts or glasses (2 cl) consumed 
- calculation of alcohol intake (g/d) based 
on standard content of ethanol of 4.8 vol. 
% for beer, 11 vol. % for wine, 33 vol. % 
for spirits (57) 
Physical 
activity (PA) 
Standardised PA questionnaire 
- separately for summer and winter 
- average time (hours) spent/week 
during 1 year 
- assessment of sport activities, biking, 
and gardening 
Standardised self-administered questionnaire 
- average time (hours) spent for sport 
activities per week 
- five categories from “no sport” to 
“regularly more than 4 hours per week” 
Smoking Standardised personal interview 
- former smoking for at least 3 months 
(yes/no/do not know) 
- current smoking (yes/no/do not know) 
- current smoking (number of 
cigarettes/day) 
Standardised self-administered questionnaire 
- current and former smoking (never, 
current (daily), current (occasionally), 
former (stopped more than 1 year ago), 
former (stopped in the past 12 months)) 
- current smoking (number of 
cigarettes/day) 
References: (10, 58, 59) 
Table 2 illustrates that there were no major differences in assessment of waist circumference, 
height, age, history of hypertension, alcohol consumption and smoking behaviour between 
EPIC-Potsdam and GNHIES. However, there were differences in the way of examining red 
meat, whole-grain bread and coffee intake. While for EPIC-Potsdam it was measured by a 
semiquantitative FFQ asking for frequencies and amounts, the FFQ of the GNHIES’ core 
survey only asked for frequencies of consumption. Thus, the average amount consumed by 
each frequency group (core survey) was estimated by using data from a survey module with a 
subsample of 4030 participants (nutrition survey). Based on dietary history interviews 
(DISHES) the typical frequencies and amounts of food intake within the last four weeks were 
acquired (55) and used to calculate the average amounts consumed per day. By combining 
information from the core survey (frequencies) and the nutrition survey (amounts) the average 
amount consumed per day for each food frequency category was estimated. This estimation 
was only based on the subsample of 4030 participants, who took part in both the core survey 
and the nutrition survey. Daily intake of meat, coffee and whole grain bread was not normally 
distributed. Therefore, individual average intake was estimated by using the median intake. 
Furthermore, whereas the food groups “coffee”, and “whole grain bread” were similar in both 
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studies, the GNHIES asks for overall meat consumption without differing between red meat 
and poultry. Finally, there are also differences in the examination of physical activity. While 
EPIC-Potsdam asks specifically for the amount of hours spent per week for biking, gardening 
and sport activities, the GNHIES examines overall physical activity in five categories ranging 
from “no physical activity at all” up to “regularly, more than 4 hours per week” (10). For 
calculating the German DRS the weekly time spent with physical activity was estimated by 
the middle time of each category band, e.g. for less than one hour a time of 0.5 hours was 
assigned, and between one and two hours a time of 1.5 hours was allocated. 
2.5 Assessment and selection of biomarkers of type 2 diabetes 
The correlation between the derived German DRS and the following biochemical markers for 
type 2 diabetes was assessed:  
whole blood HbA1c, serum glucose, serum HDL cholesterol, total serum cholesterol, 
serum triglycerides, serum alanine aminotransferase and serum γ-glutamyltransferase. 
The gel monovette system provided by Becton-Dickinson (Franklin Lakes, NJ, USA) was 
used for taking venous blood samples after a minimum fasting period of 3-hours. All blood 
samples were processed and distributed into aliquots immediately after they were taken. 
Serum samples were instantly stored at -40 °C until biochemical analyses were carried out 
(60). 
Glycosylated haemoglobin (HbA1c) was analysed in whole blood by using a test-kit of 
Recipe and a HPLC on a Diamat HPLC analyser (both Bio-Rad, Munich, Germany) (60). 
HbA1c reflects the individual’s average blood glucose levels of the past two till three months 
and can further be used for metabolic control of the diabetic patient and prediction of diabetes 
related complications (61). HbA1c was approved as diagnostic criterion for diabetes by the 
WHO only recently in 2011 (62). According to the American Diabetes Association (ADA), 
for the current investigation a level of HbA1c ≥ 6.5% was used to diagnose diabetes and an 
HbA1c level between 5.7 and 6.4% was used to identify individuals at increased risk for 
developing diabetes (intermediate hyperglycaemia) (2). 
All other metabolic markers were measured in serum. Glucose was measured by glucose 
oxidase-peroxidase-4-aminophenazone method (Merck, Darmstad, Germany) (60). The 
concentration of fasting plasma glucose (FPG) is one of the classical measures for diagnosing 
diabetes mellitus besides plasma glucose 2 hours after an OGTT. According to ADA, in the 
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present investigation a cut point for FPG1 of ≥ 126 mg/dl was used to diagnose diabetes. 
Impaired fasting glucose (IFG) as a measure for intermediate hyperglycaemia was defined by 
a FPG level of 100 till 125 mg/dl according to ADA2 (2). All serum glucose levels were 
converted into plasma glucose levels by using the following equation: venous plasma 
(mmol/l) = -0.137 + 1.047 x venous serum (mmol/l) (63). 
HDL-cholesterol was examined by using an immunoseparation-based homogeneous assay 
(WAKO, Chuo-ku, Osaka, Japan) while total cholesterol was measured with the enzymatic 
cholesterol oxidase-peroxidase-4-aminophenazone method (Merck). Triglycerides were 
assessed with glycerophosphate oxidase-peroxidase-4-aminophenazone method (Merck) (60). 
Triglycerides, HDL-and total cholesterol are metabolic markers of the fat metabolism. 
Increased levels of fasting triglycerides (> 150mg/dl), and decreased levels of HDL-
cholesterol (men: < 40 mg/dl, women: < 54 mg/dl), respectively, are associated with an 
increased CVD risk but also with insulin resistance, IFG and IGT (16, 61, 64-67). 
Furthermore, increased overall cholesterol levels (> 200 mg/dl) are related to hyperglycaemia 
(66). 
Alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) are both liver-enzymes and 
markers for liver function (61, 68, 69). Moreover, GGT is possibly a marker for oxidative 
stress (70). Increased levels of GGT (e.g. in serum > 28 U/l for men and > 18 U/l for women 
(61) and/or ALT (e.g. in serum > 22U/l for men and > 17 U/l in women(61) are also 
associated with increased levels of liver fat and an increased risk of developing diabetes and 
IGT (67-69, 71). For measuring GGT the colorimetric Granutest 100 (Merck) was used to 
conduct a kinetically colour test according to Szasz at 25°C. ALT was assessed by using 
MPR3 (Roche). 
2.6 Statistical analyses 
For all statistical analyses the statistical analysis system (SAS version 9.2, SAS Institute, Inc., 
Cary; NC, USA) was used. Statistical significance was assumed for p< 0.05. For all analyses 
a weighting factor was used to ensure statistical representativity. The weighting factor takes 
differences between the survey population and the German population in 1998, with regard to 
                                                 
1 After a fasting period of at least 8 hours (2). 
2 Another criterion for measuring increased risk for diabetes is impaired glucose tolerance (IGT) which is 
defined by 2-hour plasma glucose levels between 140 and 199 mg/dl after a 75g OGTT (2). 
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age, sex, federal state, and community size, into account (52). Significant differences between 
both genders concerning all score criteria and biomarkers (not normally distributed, 
Kolmogorov-Smirnov test, p>0.01) were examined using Wilcoxon rank-sum test for 
continuous variables and χ² test for categorical variables. A histogram showing the 
distribution of the German DRS among both men and women was prepared by creating score 
subgroups and calculating the proportion (%) of participants in each of the defined groups. 
All biomarkers were logarithmically transformed before correlation analyses to reach an 
approximately normal distribution. Correlation between German DRS and the selected log-
transformed biomarkers was calculated by using Pearson’s correlation coefficient. 
The performance of the German DRS was assessed by computing sensitivity and specificity. 
Sensitivity (true positive rate) was defined by the proportion of participants whose score 
values were above the cut offs of 300, 400, 500, 600, 700, and 800 respectively among all 
participants who suffered from undiagnosed diabetes using FPG ≥ 126 mg/dl and HbA1c 
≥ 6.5% as diagnostic criterion. Specificity (true negative rate) was defined by the proportion 
of participants whose score values were below the cut offs of 300, 400, 500, 600, 700, and 
800 respectively among those participants who do not suffer from undiagnosed diabetes (FPG 
< 126 mg/dl, HbA1c < 6.5%) (2, 15). In addition, sensitivity and specificity to identify an 
increased risk for diabetes (FPG 100-125 mg/dl, HbA1c 5.7-6.4%) were assessed by using the 
same cut offs (2). Moreover, the AUC-ROC curve was computed. The AUC value is used to 
predict the accuracy of the German DRS to discriminate between diabetic and non-diabetic 
cases and between persons at increased risk for diabetes and with non-increased risk, 
respectively (72). 
Besides, all analyses were performed with a subsample excluding pregnant women (N = 15) 
and with a subsample based on the age-groups of the EPIC-Potsdam study population 
(women: 35-65 years, men: 40-65 years). Finally, sensitivity, specificity and the AUC values 
of the computed German DRS were calculated stratified by gender. 
3. Results 
3.1 Descriptive statistics 
The whole study population comprised 6406 participants, including 3142 men and 3264 
women. Table 3 shows that women are significantly older and shorter than men. Moreover, 
their waist circumference is significantly smaller than the waist circumference of men. On 
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average men are significantly more physically active, and consume significantly more meat 
per day whereas women have a significantly higher mean daily intake of whole grain bread. A 
significantly higher proportion of men consume a moderate amount of alcohol per day 
compared to women. There are no significant differences in the average amount of coffee 
consumed per day and in the proportion of participants suffering from hypertension between 
both genders. A significantly higher percentage of men are former smokers or current heavy 
smokers compared to women. Besides, men show a significantly higher mean German DRS 
value than women and a higher probability of developing diabetes in the next five years. The 
range of the German DRS was 144.97 – 1083.12 for men and 139.18 – 908.71 for women. 
Table 3. Characteristics among men (N = 3142) and women (N = 3264) of the study population. 
 Men 
N = 3142 
Women 
N = 3264 
P value 
Component of the German DRS    
Age (years) 44.14 (43.54 – 44.74) 46.07 (45.41 – 46-72) 0.0111 
Waist circumference (cm) 96.07 (95.64 – 96.49) 84.12 (83.66 – 84.58) < 0.0001 
Height (cm) 176.41 (176.14 – 176.69) 163.54 (163.29 – 163.80) < 0.0001 
Physical activity (h/week) 1.22 (1.17 – 1.28) 0.95 (0.90 – 1.00) < 0.0001 
Moderate alcohol consumption 
(10-40 g/day) (%) 
34.20 % 11.05 % < 0.0001 
Hypertension (%) 19.79 % 21.78 % 0.2723 
Meat consumption  
(portions [each 150g]/day) 
0.63 (0.62 – 0.63) 0.56 (0.56 – 0.57) < 0.0001 
Whole grain bread consumption 
(slices [each 50g]/day) 
0.62 (0.59 – 0.64) 0.81 (0.78 – 0.83) < 0.0001 
Coffee consumption  
(cups [each 150g]/day) 
2.16 (2.11 – 2.12) 2.15 (2.09 – 2.20) 0.7938 
Former smoker (%) 27.65 % 15.54 % < 0.0001 
Current heavy smoking (%) 
    ≥20 cigarettes/day 
17.31 % 8.78 % < 0.0001 
DRS points 511.36 (505.90 – 516.82) 455.11 (449.23 – 461.00) < 0.0001 
Probability of developing diabetes (%) 5.74 % (5.39 – 6.08) 4.18 % (3.88 – 4.48) < 0.0001 
Biomarker of type 2 diabetes    
Glucose (mg/dl) 98.64 (98.07 – 99.21) 95.50 (94.96 – 96.05) < 0.0001 
HbA1c (%) 5.48 (5.45 – 5.50) 5.40 (5.38 – 5.42) < 0.0001 
HDL-cholesterol (mg/dl) 47.93 (47.39 – 48.47) 62.58 (61.91 – 63.26) < 0.0001 
Triglyceride (mg/dl) 144.09 (140.80 – 147.47) 103.25 (101.26 – 105.27) < 0.0001 
Cholesterol (mg/dl) 225.88 (224.04 – 227.74) 228.03 (226.19 – 229.88) 0.6340 
γ-glutamyltransferase (GGT) (U/l) 17.66 (17.26 – 18.07) 11.42 (11.17 – 11.67) < 0.0001 
Alanin aminotransferase (ALT) (U/l) 14.99 (14.72 – 15.27) 9.84 (9.68 – 10.00) < 0.0001 
Values are given as weighted arithmetic mean (95% CI) or weighted percentage for all Diabetes-Risk Score components and as weighted 
geometric means (95% CI) for all logarithmically transformed biomarkers. 
Mean fasting glucose was 101.64 mg/dl (CI: 99.91 mg/dl – 103.41 mg/dl) for men (N=400) and 96.47 mg/dl (CI: 95.12 mg/dl – 97.83 mg/dl) 
for women (N=660) (p-value: < 0.0001). Mean fasting triglycerides were 118.31 mg/dl (CI: 111.39 mg/dl – 125.66 mg/dl) for men (N=400) 
and 95.94 mg/dl (92.20 mg/dl – 99.82 mg/dl) for women (N=660) (p-value: < 0.0001). 
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Considering the levels of biomarkers for type 2 diabetes, men had a significantly lower HDL-
cholesterol level than women. Women had significantly lower levels of glucose, HbA1c, 
triglycerides, GGT, ALT. The level of total cholesterol did not differ significantly between 
both men and women. 
3.2 Distribution of the score 
A higher proportion of women has a low diabetes risk score and thus a lower probability of 
developing diabetes compared to men (figure 1). Especially for a score below 300 points the 
proportion of women is more than twice as high as the proportion of men. A higher 
proportion of men show a high diabetes risk score3 and thus a higher probability of 
developing diabetes compared to women. The distribution of the German DRS among men is 
similar to a normal curve whereas the score decreases steadily among women. 
Figure 1. Distribution of the German DRS and the probability of developing diabetes among men 
(N = 3142) and women (N = 3264) among a German study population. 
 
3.3 Correlation between German Diabetes Risk Score and different biomarkers of type 2 
diabetes 
The computed German DRS was significantly positively correlated with glucose, HbA1c, 
triglycerides, overall cholesterol, GGT, and ALT among both men and women (table 4). 
Among both genders it was significantly negatively correlated with HDL-cholesterol. 
                                                 
3 ≥ 500 points according to Schulze et al. (43). 
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Correlation coefficients for all biomarkers were higher among women than among men. 
Among a subsample of men (N = 400) and women (N = 660) who fasted overnight, glucose 
was significantly positively correlated (p < 0.0001) with the German DRS (correlation 
coefficient: men: 0.35; women: 0.45). Besides, there was a significant (p < 0.0001) positive 
correlation between triglycerides and the German DRS among both genders (correlation 
coefficient: men: 0.43; women: 0.45). 
Table 4. Pearson correlation among men (N = 3142) and women (N = 3264) between German DRS and 
biomarkers of type 2 diabetes. 
Biomarker Men 
N = 3142 
Women 
N = 3264 
Glucose (mg/dl) 0.30 0.40 
HbA1c (%) 0.37 0.54 
HDL-cholesterol (mg/dl) - 0.14 - 0.16 
Triglyceride (mg/dl) 0.35 0.47 
Cholesterol (mg/dl) 0.42 0.46 
γ-glutamyltransferase (GGT) (U/l) 0.33 0.39 
Alanintransferase (ALT) (U/l) 0.20 0.37 
All biomarkers were logarithmically transformed. All correlation coefficients were significant at a level of p < 0.0001. 
3.4 Performance of the German Diabetes Risk Score 
Sensitivity4 and specificity5 of the German DRS to identify cases with undiagnosed diabetes 
are illustrated in table 5 and 6. While in table 5 FPG was used to detect undiagnosed diabetes, 
in table 6 HbA1c was used for diagnosis. For both diagnostic measures sensitivity is 
decreasing with rising score values while specificity is increasing at the same time. 
Sensitivity and specificity of the German DRS to identify intermediate hyperglycaemia, was 
calculated at different cut points and by using either FPG or HbA1c as diagnostic criterion. 
The German DRS yielded lower sensitivity but higher specificity in identifying intermediate 
hyperglycaemia compared to identifying undiagnosed diabetes for each of the chosen cut 
points and for both diagnostic criteria (table 7 and 8). 
                                                 
4 Probability of a diseased subject being detected as diseased at a certain cut-off (45,46). 
5 Probability of a non-diseased subject being detected as non-diseased at a certain cut-off (45,46). 
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Table 5. Sensitivity and specificity of the German DRS to identify undiagnosed diabetes at different cut 
points based on FPG ≥ 126 mg/dl (N = 1060). 










≥ 300 49 100.0 889 87.9 12.1 
≥ 400 49 100.0 712 70.4 29.6 
≥ 500 46 93.9 501 49.6 50.4 
≥ 600 31 63.3 302 29.9 70.1 
≥ 700 19 38.8 116 11.5 88.5 
≥ 800 8 16.3 21 2.1 97.9 
FPR = false-positive rate (100-specificity) 
Table 6. Sensitivity and specificity of the German DRS to identify undiagnosed diabetes at different cut 
points based on HbA1c ≥ 6.5 % (N = 6032). 










≥ 300 238 99.6 4992 86.2 13.8 
≥ 400 235 98.3 3820 65.9 34.1 
≥ 500 218 91.2 2515 43.4 56.6 
≥ 600 172 72.0 1256 21.7 78.3 
≥ 700 93 38.9 406 7.0 93.0 
≥ 800 23 9.6 63 1.1 98.9 
FPR = false-positive rate (100-specificity) 
Table 7. Sensitivity and specificity of the German DRS to identify intermediate hyperglycaemia at 
different cut points based on FPG 100 – 125 mg/dl (N = 1060). 










≥ 300 360 96.3 529 83.0 17.0 
≥ 400 330 88.2 382 60.0 40.0 
≥ 500 265 70.9 236 37.0 63.0 
≥ 600 179 47.9 123 19.3 80.7 
≥ 700 73 19.5 43 6.8 93.2 
≥ 800 15 4.0 6 0.9 99.1 
FPR = false-positive rate (100-specificity) 
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Table 8. Sensitivity and specificity of the German DRS to identify intermediate hyperglycaemia at 
different cut points based on HbA1c 5.7 – 6.4 % (N = 6032). 










≥ 300 1686 95.8 3306 82.0 18.0 
≥ 400 1520 86.4 2300 57.0 43.0 
≥ 500 1192 67.7 1323 32.8 67.2 
≥ 600 693 39.4 563 14.0 86.0 
≥ 700 256 14.5 150 3.7 96.3 
≥ 800 47 2.7 16 0.4 99.6 
FPR = false-positive rate (100-specificity) 
The accuracy of the German DRS for the prediction of undiagnosed diabetes was measured 
by using the American Diabetes Association’s (ADA) diagnostic criterion of FPG 
≥126 mg/dl. In a further step, it was measured by using the diagnostic criterion of 
HbA1c ≥ 6.5%. For detection of intermediate hyperglycaemia, a range for FPG of 100-
125 mg/dl and a range for HbA1c of 5.7-6.4% both according to ADA were used (2). The 
AUC for prediction of undiagnosed diabetes was 0.79 when using FPG and 0.84 when using 
HbA1c as diagnostic criterion (presented in figure 2). 
Figure 2. ROC curve of the German DRS for prediction of undiagnosed diabetes using FPG ≥126 mg/dl 
(N = 1060) and using HbA1c ≥6.5% (N = 6032). 
  
The results for the prediction of intermediate hyperglycaemia are presented in figure 3. The 
AUC value based on FPG was 0.72 while the AUC value based on HbA1c was 0.74. 
AUC=0.79 














1 – specificty 
FPG ≥ 126 mg/dl HbA1c ≥ 6.5% 
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Figure 3. ROC curve of the German DRS for prediction of intermediate hyperglycaemia using FPG 100-
125 mg/dl (N = 1060)  and using HbA1c 5.7-6.4% (N = 6032). 
  
3.5 Sensitivity analyses 
Analysing the performance of the German DRS stratified by gender (see appendix 1) yielded 
an about 2 times higher specificity among women than among men for the cut offs of ≥300 
and ≥400. These results were valid for both undiagnosed diabetes and intermediate 
hyperglycaemia and for both FPG and HbA1c as diagnostic criterion. When FPG was used as 
diagnostic criterion, sensitivity for undiagnosed diabetes was at least 1.5 times higher among 
women than among men above the cut offs of 700 and 800 points. Based on FPG, sensitivity 
for intermediate hyperglycaemia was at least 2 times higher among men above the cut offs of 
700 and 800 points. The AUC values among women were higher than those calculated for 
men. For example, the AUC value for undiagnosed diabetes based on FPG was 0.87 among 
women and 0.67 among men, based on HbA1c it was 0.86 among women and 0.82 among 
men. 
Statistical analyses based on a subsample, taking only the age-group of the EPIC-Potsdam 
study into account6 (appendix 2), led to similar results for the descriptive statistics while the 
distribution of the calculated German DRS among women changed. On average women were 
still more likely than men to have a lower score value, but the distribution among women was 
closer to a normal distribution, though, still slightly skewed to the left. All biomarkers for 
                                                 
6 women: 35-65 years, men: 40-65 years 
AUC=0.74 















FPG 100 – 125 mg/dl HbA1c 5.7 – 6.4 % 
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type 2 diabetes were significantly correlated with the computed German DRS. Correlation 
coefficients were lower for most biomarkers than among the complete survey population 
except for triglycerides and ALT among women. There were no major differences in 
sensitivity and specificity between the diagnostic criteria FPG and HbA1c for both 
undiagnosed diabetes and intermediate hyperglycaemia. The calculated AUC values for the 
subsample where lower compared to the complete sample. 
All statistical analysis were performed on a subsample excluding all pregnant women 
(N = 15). The results were very similar to the results of the whole sample and were not 
reported. 
4. Discussion 
The aim of the present investigation was to examine the distribution of the computed German 
DRS, to scrutinize its correlation with biomarkers related to type 2 diabetes, and to analyse its 
performance as a screening tool. 
4.1 Results 
Distribution of the score 
On average, men reach a higher German DRS than women and consequently also have a 
higher probability of developing type 2 diabetes in the following 5 years. In one of their 
studies, Schulze et al. found a similar result with men on average yielding higher German 
DRS values than women (40). Other studies found a higher risk of developing diabetes among 
men than among women as well (20, 31, 35, 67). However, the prevalence of diagnosed 
diabetes was higher among German women than among German men in 2009 (6). These 
findings suggest that there might be a higher number of men suffering from undiagnosed 
diabetes, whereas diabetes among women is more often diagnosed. 
Moreover, also the distribution of the score among women and men differed. While on 
average women were more likely to achieve a lower score, especially lower than 300 points 
(distribution skewed to the left), men on average were more likely to yield a higher score 
(≥500 points) (normal distribution). Analyses of the score distribution in a subsample 
including only the age-groups of the EPIC-Potsdam study, i.e. women aged 35-65 years and 
men aged 40-65 years, showed a decreased proportion of women with a mean score lower 
than 300 points. In a further step, the score distribution among women younger than 35 years, 
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men younger than 40 years, and women and men older than 65 years was analysed. 
Differences in the distribution among the examined age-groups indicate, that young women 
are responsible for the high proportion of low average score values in the female survey 
population. On the contrary, the average score value increases among both middle aged and 
elderly women and men, reflecting the increasing prevalence of diabetes with rising age (20). 
The positive association between age and the risk of developing diabetes is further reflected 
by its consideration in the equation of the German DRS (10). Furthermore, among all age-
groups on average women achieve lower score values than men exhibiting the decreased risk 
for diabetes among women (20). However, the distribution of the score among women aged 
35-65 years is more similar to the score distribution of men aged 40-65 years than the score 
distribution of women and men among the whole survey population. This finding suggests 
that the risk of diabetes is more similar among women and men aged 35-65 years than among 
women and men aged 18-79 years. 
A less healthy lifestyle contributed more to a high risk of diabetes among men than among 
women. For example, in the present study population on average men show a significantly 
higher consumption of red meat, a lower consumption of whole grain bread, and a higher 
proportion of heavy smokers and former smokers compared to women. All of these factors 
are positively associated with high risk of diabetes (10). In addition, on average men also 
have a significantly higher waist circumference than women, which is also positively 
associated with diabetes risk (10). On the other hand, in the present study on average men are 
significantly younger, taller, and more physically active than women. Besides, a higher 
proportion of men consume moderate amounts of alcohol per day compared to women. All of 
which are factors negatively associated with diabetes risk (10). These findings indicate that 
among the present survey population the differences in score values and thus in diabetes risk 
among both genders are related to differences in nutritional behaviour (red meat and whole 
grain bread intake), the high proportion of male heavy and former smokers, and a higher waist 
circumference among men. 
Association with biomarkers related to type 2 diabetes 
The higher average score value among men is accompanied by a significantly lower mean 
HDL-cholesterol level and significantly higher average levels of glucose, HbA1c, 
triglycerides, GGT, and ALT compared to women. Similar results have been found in other 
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studies. For example, Schulze et al. found higher levels of glucose, GGT, and triglycerides 
and also lower levels of HDL-cholesterol among men (40). In addition, Nannipieri et al. 
detected higher ALT and GGT levels among men than among women (69). Increased levels 
of plasma glucose, HbA1c, triglycerides, GGT, and ALT and decreased levels of HDL-
cholesterol are associated with a higher prevalence of diabetes and with increased risk for 
diabetes (2, 62, 65, 66, 69). Consequently, the biomarker profile of men reflects their higher 
German DRS and further explains their higher risk of diabetes. 
Among both men and women the calculated German DRS was significantly positively 
correlated with glucose, HbA1c, total cholesterol, triglycerides, GGT, and ALT. In addition, it 
was significantly negatively associated with HDL-cholesterol. The correlation coefficients 
were higher for fasting glucose and fasting triglycerides compared to the non-fasting 
coefficients. The current findings are comparable to the results of Schulze et al., who also 
found significant positive correlations between German DRS and glucose, HbA1c, 
triglycerides, and GGT and a significant negative correlation between score and HDL-
cholesterol among both genders (40). Generally, correlation coefficients were similar in the 
present investigation and the study of Schulze et al. Although, the correlation coefficients 
with glucose and HbA1c in the current study were at least 1.5 times higher among both 
genders than those found by Schulze et al. On the other hand, the correlation coefficient with 
HDL-cholesterol was almost 2 times higher among women and about 1.5 times higher among 
men in the study of Schulze et al. compared to the current investigation. In both studies, 
women showed higher correlation coefficients than men, except for glucose in the study of 
Schulze et al. (40). An association between prevalent diabetes and different biomarkers, and 
intermediate hyperglycaemia and different biomarkers, respectively, was found in other 
studies as well. For example, for HDL-cholesterol, total cholesterol, triglycerides, ALT, and 
GGT (20, 66, 67, 69). Finally, the present investigation was able to detect correlations 
between the German DRS and all of the studied biomarkers of type 2 diabetes. 
Performance of the German DRS 
Based on data of a German study population, the German DRS yielded a 
sensitivity/specificity of 93.9/50.4 for undiagnosed diabetes based on FPG and 91.2/56.6 for 
undiagnosed diabetes based on HbA1c (cut off ≥500). These results are comparable to the 
findings in the MeSyBePo study. Here, for the same cut off, the German DRS yielded a 
28 
 
sensitivity/specificity of 94/43% based on FPG. However, in the TÜF study it yielded lower 
sensitivity, but higher specificity (83/72%) based on FPG (10). Other diabetes risk scores 
assessed in Germany yielded lower sensitivity combined with higher specificity and in some 
cases also a lower specificity (33, 35, 36). Nevertheless, sensitivity and specificity always 
depend on the chosen cut-off (15), therefore it might be difficult to compare results of 
different studies using different cut points. 
In the present investigation, the accuracy of the German DRS for detection of undiagnosed 
diabetes was 0.79 based on FPG and 0.84 based on HbA1c. Consequently, the accuracy of the 
German DRS based on FPG was higher than in the MeSyBePo study (AUC=0.75) but lower 
than in the TÜF study (AUC=0.83) (10). Moreover, compared to most other studies, where 
diabetes risk scores have been applied to a different study population, the German DRS 
yielded a higher AUC value for detection of undiagnosed diabetes. For example, Rathmann et 
al. found an AUC value of 0.67 for the Cambridge DRS, 0.65 for the FINDRISK, and 0.61 
for the Rotterdam Diabetes Study Questionnaire (33). Besides, in a study of Bergmann et al. 
the application of the German FINDRISK version yielded 0.75. Only Li et al. detected a 
higher accuracy (AUC=0.81) when applying the German FINDRISK version, and Rathmann 
et al. found an AUC value of 0.90 when applying the predictive clinical model of the San 
Antonio Heart Study (33, 36). However, both Li et al. and Bergmann et al. included history of 
high blood glucose in their score. It encompasses intermediate hyperglycaemia and diabetes 
itself, which is obviously positively related to identification of undiagnosed diabetes and 
therefore might yield to a higher accuracy for detection of undiagnosed diabetes. Furthermore, 
the predictive clinical model of the San Antonio Heart Study included invasive measures, 
which have been shown to improve accuracy (36). As a result, it is difficult to compare the 
AUC value of a score using only non-invasive measures, like the German DRS, and a score 
using further invasive measures. 
With regard to identification of intermediate hyperglycaemia, in their study, Schulze et al. 
found a sensitivity/specificity of 74/71% (cut off ≥500) based on FPG between 100 and 125 
mg/dl (40). In the present analyses, rather lower levels of sensitivity/specificity for the 
detection of intermediate hyperglycaemia were found (70.9/62.9% based on FPG; 67.7/67.2% 
based on HbA1c). Besides, while in the current investigation the German DRS yielded an 
AUC value of 0.72 (FPG) and 0.74 (HbA1c) for detection of intermediate hyperglycaemia, 
Schulze et al. found an AUC of 0.79 based on FPG in their study. This indicates a poorer 
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performance of the German DRS in the present investigation (40). However, the difference is 
rather moderate and it has been shown in previous studies that the performance of risk scores 
is better in the original study population than in other study populations (33, 42). 
Differences in accuracy, but also in sensitivity and specificity, between different scores might 
further occur due to differences in diagnostic measures used for identification of cases of 
undiagnosed diabetes. For example, Li et al. and Rathmann et al. used both FPG ≥ 126 mg/dl 
and a 2 hour post-load glucose level of ≥ 200 mg/dl as diagnostic criteria (33, 36). In the 
present investigation FPG ≥ 126 mg/dl and HbA1c ≥ 6.5% were used. So far, HbA1c has not 
been used as diagnostic criterion in any of the studies assessed. Thus, further comparison of 
the current findings based on HbA1c with the performance of other scores was not possible. 
4.2 Strengths and limitations 
The current investigation is the first study applying a diabetes risk score to such a large 
representative sample of the residential population of Germany, comprising subjects aged 18-
79 years. A weighting factor was used for all analyses to improve representativity. In 
addition, the applied German DRS was the only risk score developed based on a large 
German cohort study (EPIC-Potsdam), which improves its applicability in a German study 
population (48). Moreover, information about a high number of biomarkers related to 
pathophysiology of type 2 diabetes was available and could be included in the current 
analyses. 
The present analyses is the only investigation examining the performance of a diabetes risk 
score in a German population by using HbA1c as diagnostic criterion for diabetes. HbA1c has 
been approved by WHO only recently in 2011 as new diagnostic criterion for diabetes (62). 
Therefore, it was used as diagnostic criterion only in a few studies yet and not in any of the 
studies assessed. 
Finally, the score variables age, hypertension, height, waist circumference, former smoking, 
current smoking, and alcohol consumption were assessed in a similar way in EPIC-Potsdam 
and in the GNHIES, improving the comparability of results between the original study and the 
present evaluation. 
Alongside with the presented strengths, there were also some limitations, which will be 
discussed in the following. Some population groups might still be underrepresented in the 
survey sample, e.g. it has been shown that poor self-rated health is more common among non-
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participants of health surveys than among participants (73, 74). However, analysis of the self-
reported health status of non-respondents of the GNHIES showed no major differences in 
self-rated health between respondents and non-respondents (52). Moreover, both GNHIES 
and EPIC-Potsdam only included certain age-groups. In the GNHIES people above the age of 
80 years did not take part, therefore there might be differences between the performance of 
the German DRS among elderly and the performance of the score in the present investigation. 
On the other hand, in EPIC-Potsdam only women aged 35-65 years and men aged 40-65 years 
participated. As a result, the generalizability of the German DRS to age-groups younger than 
35 years and older than 65 years might be limited. In addition, in both GNHIES and EPIC-
Potsdam participants with migration background were underrepresented (52). Thus, the 
German DRS might show a different sensitivity, specificity and discriminatory ability among 
the general German population than among the current sample and among the EPIC-Potsdam 
sample. 
One of the most commonly used measures for diagnosing diabetes, besides 2 hour post-load 
glucose level, is FPG. However, only serum glucose was analysed in the GNHIES and 
therefore had to be converted into plasma glucose before further analyses by using the 
equation of Carstensen et al. (63). In addition, there was only a lower number of fasting blood 
samples available. Therefore, only information of 1060 participants regarding fasting glucose 
levels could be used for analyses. However, as fasting is no prerequisite for measuring HbA1c 
(62), this information could be analysed for a higher number of participants (N=6032). 
There were some differences in the assessment of the score variables between GNHIES and 
EPIC-Potsdam. Consumption of red meat, for example, was overestimated in the GNHIES, as 
participants were solely asked for overall meat intake and not differentiated for red meat and 
poultry consumption. However, compared to, e.g. age, waist circumference, and height the 
influence of red meat consumption to the overall score value is rather low. For example, on 
average men are 44.14 years old, 176.41 cm tall, and their waist circumference is 96.07 cm, 
while the average intake of red meat is only 0.63 portions per day. Moreover, for the core 
survey there was only information available about the frequencies of consumption of whole 
grain bread, red meat, and coffee, but not about the consumed amount per day. Thus, the 
average daily amount of intake could only be estimated for each category of the core survey’s 
FFQ, based on data of a survey module consisting of a subsample of 4030 subjects. As a 
consequence, the nutritional components of the score were calculated based on the median 
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intake of each category of the core survey’s FFQ, instead of taking the individual daily intake 
into account. Therefore, the intake of red meat, whole grain bread and coffee might have been 
over- or underestimated. However, due to the small daily intake of slices of whole grain 
bread, portions of red meat, and cups of coffee (for men on average 0.62 slices of whole grain 
bread, 0.63 portions of red meat, and 2.16 cups of coffee) the influence is rather small. 
In addition, there were differences in the assessment of physical activity. While in EPIC-
Potsdam sports, biking and gardening were assessed, in the GNHIES there was only a general 
question about sports participation. Furthermore, the questionnaire asked in categories. 
Therefore, for each category the time was estimated as middle time of each category band, i.e. 
less than 1 hour was allocated with a time of 0.5 hours, between 1 and 2 hours a time of 1.5 
hours was assigned. People spending more than 4 hours per week on doing exercise were 
allocated with an average time of 4.5 hours per week. As a result, the average time per week 
spend on doing exercise might have been slightly overestimated for some groups and might 
have been underestimated for the highest category. However, the average time spent on 
physical activity is only 1.22 h/week among men and 0.95 h/week among women, and should 
therefore only have a small influence on the final level of the German DRS. 
Finally, it has to be taken into account that in both GNHIES and EPIC-Potsdam most 
information relevant for calculation of the score was gathered through self-administered 
questionnaires and could therefore be susceptible to self-reporting bias. For example, there 
might have been misreporting for smoking, eating habits, and physical activity due to social 
desirability bias (10). 
Contrarily, to the present study Rathmann et al. found a higher discriminatory ability of their 
prediction model among men than among women. However, their model was based on a 
study population aged 55-74 years where the influence of age was less important (31). 
Application of the German DRS in a subsample, including the same age-groups as in EPIC-
Potsdam, showed further differences in the performance of the score among the whole survey 
population and among the subsample. These findings indicate that the performance of 
different scores might vary between men and women and between different age-groups. 
5. Conclusion 
All together, the present evaluation identified the German DRS as an accurate screening tool 
for undiagnosed diabetes and intermediate hyperglycaemia among the survey population. This 
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indicates that it could possibly be used as a screening tool for undiagnosed diabetes as well as 
for intermediate hyperglycaemia on population level. However, when implementing the 
German DRS as a screening tool, it should be considered that it showed a higher 
discriminatory ability among women than among men (higher AUC values). 
Based on the current results, further research with regard to differences in discriminatory 
ability between women and men and between different age-groups would be useful. In 
addition, it would be worth to evaluate the ability of the German DRS to predict the risk of 
developing future diabetes by using longitudinal data. Besides, a comparison of the 
performance of different versions of the German DRS, e.g. classic version, and simplified 
version, would help to further assess the strengths of the German DRS. Finally, it would be 
useful to examine additional possibilities for identification of high risk groups for developing 
future diabetes improving efficiency of the German DRS as a screening tool among the 
German population. 
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Appendix 1 – Stratification by gender 
A) Undiagnosed diabetes 
I) Sensitivity and specificity of the German DRS among women to identify undiagnosed diabetes at 
different cut points based on FPG ≥ 126 mg/dl (N = 660). 










≥ 300 23 100.0 541 84.9 15.1 
≥ 400 23 100.0 416 65.3 34.7 
≥ 500 22 95.7 260 40.8 59.2 
≥ 600 15 65.2 135 21.2 78.8 
≥ 700 11 47.8 44 6.9 93.1 
≥ 800 6 26.1 4 0.6 99.4 
FPR = false-positive rate (100-specificity) 
II) Sensitivity and specificity of the German DRS among men to identify undiagnosed diabetes at different 
cut points based on FPG ≥ 126 mg/dl (N = 400). 










≥ 300 26 100.0 348 93.0 7.0 
≥ 400 26 100.0 296 79.1 20.9 
≥ 500 24 92.3 241 64.4 35.6 
≥ 600 16 61.5 167 44.7 55.3 
≥ 700 8 30.8 72 19.3 80.7 
≥ 800 2 7.7 17 4.5 95.5 
FPR = false-positive rate (100-specificity) 
III) Sensitivity and specificity of the German DRS among women to identify undiagnosed diabetes at 
different cut points based on HbA1c ≥ 6.5 % (N = 3076). 










≥ 300 99 100.0 2400 80.6 19.4 
≥ 400 97 98.0 1698 57.0 43.0 
≥ 500 90 90.9 1046 35.1 64.9 
≥ 600 67 67.7 507 17.0 83.0 
≥ 700 35 35.4 168 5.6 94.4 
≥ 800 8 8.1 28 0.9 99.1 
FPR = false-positive rate (100-specificity) 
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IV) Sensitivity and specificity of the German DRS among men to identify undiagnosed diabetes at 
different cut points based on HbA1c ≥ 6.5 % (N = 2956). 










≥ 300 139 99.3 2592 92.0 8.0 
≥ 400 138 98.6 2122 75.4 24.6 
≥ 500 128 91.4 1469 52.2 47.8 
≥ 600 105 75.0 749 26.6 73.4 
≥ 700 58 41.4 238 8.5 91.5 
≥ 800 15 10.7 35 1.2 98.8 
FPR = false-positive rate (100-specificity) 
I) ROC curve of the German DRS for prediction of undiagnosed diabetes among women (N=660) and men 
(N=400) using FPG ≥126 mg/dl. 
  
II) ROC curve of the German DRS for prediction of undiagnosed diabetes among women (N=3076) and 
men (N=2956) using HbA1c ≥6.5%. 
  
AUC=0.87 
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B) Intermediate hyperglycemia 
V) Sensitivity and specificity of the German DRS among women to identify intermediate hyperglycaemia 
at different cut points based on FPG 100 – 125 mg/dl (N = 637). 










≥ 300 183 95.8 358 80.3 19.7 
≥ 400 167 87.4 249 55.8 44.2 
≥ 500 130 68.1 130 29.1 70.9 
≥ 600 76 39.8 59 13.2 86.8 
≥ 700 24 12.6 20 4.5 95.5 
≥ 800 1 0.5 3 0.7 99.3 
FPR = false-positive rate (100-specificity) 
VI) Sensitivity and specificity of the German DRS among men to identify intermediate hyperglycaemia at 
different cut points based on FPG 100 – 125 mg/dl (N = 373). 










≥ 300 177 96.7 171 89.5 10.5 
≥ 400 163 89.1 133 69.6 30.4 
≥ 500 135 73.8 106 55.5 44.5 
≥ 600 103 56.3 64 33.5 66.5 
≥ 700 49 26.8 23 12.0 88.0 
≥ 800 14 7.7 3 1.6 98.4 
FPR = false-positive rate (100-specificity) 
VII) Sensitivity and specificity of the German DRS among women to identify intermediate 
hyperglycaemia at different cut points based on HbA1c 5.7 – 6.4 % (N = 2977). 










≥ 300 781 95.5 1619 75.0 25.0 
≥ 400 700 85.6 998 46.2 53.8 
≥ 500 539 65.9 507 23.5 76.5 
≥ 600 325 39.7 182 8.4 91.6 
≥ 700 123 15.0 45 2.1 97.9 
≥ 800 23 2.8 5 0.2 99.8 
FPR = false-positive rate (100-specificity) 
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VIII) Sensitivity and specificity of the German DRS among men to identify intermediate hyperglycaemia 
at different cut points based on HbA1c 5.7 – 6.4 % (N = 2816). 










≥ 300 905 96.1 1687 90.0 10.0 
≥ 400 820 87.05 1302 69.5 30.5 
≥ 500 653 69.3 816 43.5 56.5 
≥ 600 368 39.1 381 20.3 79.7 
≥ 700 133 14.1 105 5.6 94.4 
≥ 800 24 2.5 11 0.6 99.4 
FPR = false-positive rate (100-specificity) 
III) ROC curve of the German DRS for prediction of intermediate hyperglycaemia among women 
(N=637) and men (N=373) using FPG 100-125 mg/dl. 
  
AUC=0.65 


















IV) ROC curve of the German DRS for prediction of intermediate hyperglycaemia among women 
(N=2977) and men (N=2816) using HbA1c 5.7-6.4%. 
  
AUC=0.67 


















Appendix 2 – Analyses for a subpopulation: women aged 35-65 years, men aged 40-65 
years 
Descriptive statistics 
Characteristics among men (N = 1457) and women (N = 1931) of the study population. 
 Men 
N = 1457 
Women 
N = 1931 
P value 
Components of the German DRS    
Age (years) 51.51 (51.09 – 51.92) 49.17 (48.73 – 49.61) < 0.0001 
Waist circumference (cm) 99.62 (99.08 – 100.17) 85.86 (85.27 – 86.44) < 0.0001 
Height (cm) 175.35 (174.99 – 175.71) 163.30 (163.01 – 163.60) < 0.0001 
Physical activity (h/week) 1.05 (0.97 – 1.12) 0.94 (0.88 – 1.01) 0.3224 
Moderate alcohol consumption 
(10-40 g/day) (%) 
36.5% 13.6% < 0.0001 
Hypertension (%) 25.09% 23.12% 0.1961 
Meat consumption  
(portions [each 150g]/day) 
0.62 (0.61 – 0.63) 0.57 (0.57 – 0.58) < 0.0001 
Whole grain bread consumption 
(slices [each 50g]/day) 
0.66 (0.63 – 0.70) 0.84 (0.81 – 0.87) < 0.0001 
Coffee consumption  
(cups [each 150g]/day) 
2.32 (2.25 – 2.39) 2.35 (2.29 – 2.41) 0.2252 
Former smoker (%) 34.29% 19.52% < 0.0001 
Current heavy smoking (%) 
    ≥20 cigarettes/day 
15.61% 9.47% < 0.0001 
DRS points 573.38 (567.99 – 578.77) 482.73 (476.88 – 488.58) < 0.0001 
Probability of developing diabetes 
(%) 
6.86% (6.41 – 7.32) 3.9% (3.59 – 4.22) < 0.0001 
Biomarker of type 2 diabetes    
Plasmaglucose (mg/dl) 101.00 (100.12 – 101.89) 96.28 (95.68 – 96.89) < 0.0001 
HbA1c (%) 5.58 (5.54 – 5.62) 5.43 (5.40 – 5.45) < 0.0001 
HDL-cholesterol (mg/dl) 48.45 (47.63 – 49.28) 63.79 (62.93 – 64.66) < 0.0001 
Triglyceride (mg/dl) 164.77 (159.35 – 170.36) 105.57 (102.97 – 108.23) < 0.0001 
Cholesterol (mg/dl) 242.64 (240.14 – 245.16) 234.61 (232.44 – 236.80) < 0.0001 
γ-glutamyltransferase (GGT) (U/l) 20.34 (19.63 – 21.07) 12.20 (11.85 – 12.55) < 0.0001 
Alanin aminotransferase (ALT) (U/l) 16.12 (15.72 – 16.52) 10.30 (10.09 – 10.51) < 0.0001 
Values are given as weighted arithmetic mean (95% confidence interval) or weighted percentage for all Diabetes-Risk Score 
components and as weighted geometric means (95% confidence interval) for all logarithmically transformed biomarkers. 
Mean fasting plasma glucose was 104.85 mg/dl (CI: 102.00 mg/dl – 107.78 mg/dl) for men (N=177)and 96.78 mg/dl (CI: 
95.38 mg/dl – 98.19 mg/dl) for women (N=444) (p-value: < 0.0001). Mean fasting triglycerides was 136.55 mg/dl (CI: 




Distribution of the German DRS and the probability of developing diabetes among men (N = 1457) and 
women (N = 1931) in a national sample of the German population. 
 
Correlation 
Pearson correlation among men (N = 1457) and women (N = 1931) between German DRS and biomarkers 
of type 2 diabetes. 
Biomarker Men 
N = 3142 
Women 
N = 3264 
Glucose (mg/dl) 0.21 0.30 
HbA1c (%) 0.20 0.45 
HDL-cholesterol (mg/dl) -0.22 -0.29 
Triglyceride (mg/dl) 0.24 0.47 
Cholesterol (mg/dl) 0.12 0.32 
γ-glutamyltransferase (GGT) (U/l) 0.23 0.34 
Alanintransferase (ALT) (U/l) 0.22 0.41 
All biomarkers were logarithmically transformed. All correlation coefficients were significant at a level of 
p < 0.0001. 
Among a subsample of men (N = 181) and women (N = 449) who fasted overnight glucose 
was significantly correlated with the computed German DRS (correlation coefficient: men: 
0.21 (p=0.0061); women: 0.33 (p<0.0001)). Besides, there was a significant (p < 0.0001) 
correlation between triglycerides and the German DRS among both genders (correlation 
coefficient: men: 0.29; women: 0.44). 



















































































































Sensitivity and specificity of the German DRS to identify undiagnosed diabetes at different cut points 
based on FPG ≥ 126 mg/dl (N = 621). 










≥ 300 30 100.0 571 96.6 3.4 
≥ 400 30 100.0 490 82.9 17.1 
≥ 500 27 90.0 326 55.2 44.8 
≥ 600 16 53.3 174 29.4 70.6 
≥ 700 6 20.0 58 9.8 90.2 
≥ 800 2 6.7 10 1.7 98.3 
FPR = false-positive rate (100-specificity) 
Sensitivity and specificity of the German DRS to identify undiagnosed diabetes at different cut points 
based on HbA1c ≥ 6.5 % (N = 3223). 










≥ 300 136 100.0 2994 97.0 3.0 
≥ 400 133 97.8 2559 82.9 17.1 
≥ 500 119 87.5 1732 56.1 43.9 
≥ 600 87 64.0 780 25.3 74.7 
≥ 700 41 30.1 207 6.7 93.3 
≥ 800 9 6.6 31 1.0 99.0 
FPR = false-positive rate (100-specificity) 
Sensitivity and specificity of the German DRS to identify intermediate hyperglycaemia at different cut 
points based on FPG 100 – 125 mg/dl (N = 591). 










≥ 300 225 98.3 346 95.6 4.4 
≥ 400 214 93.4 276 76.2 23.8 
≥ 500 163 71.2 163 45.0 55.0 
≥ 600 98 42.8 76 21.0 79.0 
≥ 700 37 16.2 21 5.8 94.2 
≥ 800 7 3.1 3 0.8 99.2 
FPR = false-positive rate (100-specificity) 
46 
 
Sensitivity and specificity of the German DRS to identify intermediate hyperglycaemia at different cut 
points based on HbA1c 5.7 – 6.4 % (N = 3087). 










≥ 300 1059 99.1 1935 95.9 4.1 
≥ 400 998 93.4 1561 77.4 22.6 
≥ 500 781 73.1 951 47.1 52.9 
≥ 600 405 37.9 375 18.6 81.4 
≥ 700 117 10.9 90 4.5 95.5 
≥ 800 24 2.2 7 0.3 99.7 
FPR = false-positive rate (100-specificity) 
ROC curve of the German DRS for prediction of undiagnosed diabetes using FPG ≥126 mg/dl (N = 621) and 
using HbA1c ≥6.5% (N = 3223). 
  
AUC=0.73 














1 – specificty 
FPG ≥ 126 mg/dl HbA1c ≥ 6.5% 
47 
 
ROC curve of the German DRS for prediction of intermediate hyperglycaemia using FPG 100-125 mg/dl 



















FPG 100 – 125 mg/dl HbA1c 5.7 – 6.4 % 
